Instituto De Pesquisa Clinica de Campinas - Ipecc
Instituto De Pesquisa Clinica de Campinas - Ipecc
Rua Oswaldo Oscar Barthelson, 1209 - Jardim Pauliceia, Campinas - SP, 13060-080
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Carla Vicente
Flavia Guimarães
Marina Saraiva Marengo
Hellen Futemma
Jose Francisco Saraiva
Carolina Maschia
Wendel Renan Garcia
Natalia Baraldi
Midia Kaneblai Martins Costa
Sylka Rodovalho
Nayara Vilella
Camila Ormundo
Alexandre Pieri
Open studies
Cardiovascular disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
Obesity
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Heart failure
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Chronic obstructive pulmonary disease
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) - EMBARK - AstraZenecaSee more
Elevated Lipoprotein A
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
Alzheimer disease
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) - ADAGIO-1 - Bristol-Myers SquibbSee more
Cardiac arrhythmia
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation - ROXI-ATLAS - Regeneron PharmaceuticalsSee more
